X Xu

Summary

Affiliation: Rigel Pharmaceuticals
Country: USA

Publications

  1. ncbi request reprint Dominant effector genetics in mammalian cells
    X Xu
    Rigel, Inc, San Francisco, California, USA
    Nat Genet 27:23-9. 2001
  2. ncbi request reprint Identification of RIP3, a RIP-like kinase that activates apoptosis and NFkappaB
    P W Yu
    Rigel, Inc 240 East Grand Ave, South San Francisco, California 94080, USA
    Curr Biol 9:539-42. 1999

Collaborators

Detail Information

Publications2

  1. ncbi request reprint Dominant effector genetics in mammalian cells
    X Xu
    Rigel, Inc, San Francisco, California, USA
    Nat Genet 27:23-9. 2001
    ..Our data indicate that trans-dominant effector peptides can point to potential mechanisms by which signaling systems operate. Such tools may be useful in functional genomic analysis of signaling pathways in mammalian disease processes...
  2. ncbi request reprint Identification of RIP3, a RIP-like kinase that activates apoptosis and NFkappaB
    P W Yu
    Rigel, Inc 240 East Grand Ave, South San Francisco, California 94080, USA
    Curr Biol 9:539-42. 1999
    ..Overexpression of a dominant-negative mutant of RIP3 strongly inhibited the caspase activation but not the NFkappaB activation induced by TNFalpha. Therefore, RIP3 appears to function as an intermediary in TNFalpha-induced apoptosis...